← Browse by Condition
Medical Condition

esophageal squamous cell carcinoma escc

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for esophageal squamous cell carcinoma escc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — esophageal squamous cell carcinoma escc Clinical Trials

How many clinical trials are currently recruiting for esophageal squamous cell carcinoma escc?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for esophageal squamous cell carcinoma escc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for esophageal squamous cell carcinoma escc?
esophageal squamous cell carcinoma escc research spans Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a esophageal squamous cell carcinoma escc clinical trial?
Eligibility criteria for esophageal squamous cell carcinoma escc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
3
Phase 3
1
Top Sponsors
City of Hope Medical Center 1 trial
Fudan University 1 trial
Qilu Pharmaceutical Co., Ltd. 1 trial
Ming-Yu Lien 1 trial
Chuangzhen Chen 1 trial

Recruiting Clinical Trials

NCT07224750
Recruiting
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Enrollment
1,000 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →
NCT07697859
Recruiting
PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
Enrollment
354 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT07463573 Phase 3
Recruiting
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment
466 pts
Location
China
Sponsor
Qilu Pharmaceutical Co., Ltd.
View Trial →
NCT07039162 Phase 2
Recruiting
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
Enrollment
45 pts
Location
Taiwan
Sponsor
Ming-Yu Lien
View Trial →
NCT07339488 Phase 2
Recruiting
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Enrollment
39 pts
Location
China
Sponsor
Chuangzhen Chen
View Trial →
NCT06912074 Phase 2
Recruiting
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Enrollment
134 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →

Related Conditions

hepatocellular carcinoma hcc (1) cholangiocarcinoma (1) pancreatic ductal adenocarcinoma pdac (1) gastric cancer gc (1) colorectal cancer screening (1) locally advanced unresectable esophageal cancer (1) borderline resectable carcinoma (1) unresectable cancer (1) immune checkpoint inhibitor (1) chemotherapy (1) radiotherapy (1) tislelizumab (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology